Cited by 1,258Polyomavirus and related diseasesCancer Immunotherapy and BiomarkersNonmelanoma Skin Cancer Studies

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Open access

Nghiem, Paul T., Bhatia, Shailender, Lipson, Evan J., Kudchadkar, Ragini R., Miller, Natalie J., Annamalai, Lakshmanan, Berry, Sneha, Chartash, Elliot K., Daud, Adil, Fling, Steven P., Friedlander, Philip A., Kluger, Harriet M., Kohrt, Holbrook E., Lundgren, Lisa, Margolin, Kim, Mitchell, Alan, Olencki, Thomas, Pardoll, Drew M., Reddy, Sunil A., Shantha, Erica M., Sharfman, William H., Sharon, Elad, Shemanski, Lynn R., Shinohara, Michi M., Sunshine, Joel C., Taube, Janis M., Thompson, John A., Townson, Steven M., Yearley, Jennifer H., Topalian, Suzanne L., Cheever, Martin A.·2016·New England Journal of Medicine

DOI 10.1056/nejmoa1603702PMC PMC4927341

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma often responds to chemotherapy, but responses are transient. Blocking the programmed death 1 (PD-1) immune inhibitory pathway is of interest, because these tumors often express PD-L1, and MCPyV-specific T cells express PD-1. METHODS: In this multicenter, phase 2, noncontrolled study, we assigned adults with advanced Merkel-cell carcinoma who had received no previous systemic therapy to receive pembrolizumab (anti-PD-1) at a dose of 2 mg per kilogram of body weight every 3 weeks. The primary end point was the objective response rate according to Response Evaluation Criteria in Solid Tumors, version 1.1. Efficacy was correlated with tumor viral status, as assessed by serologic and immunohistochemical testing. RESULTS: A total of 26 patients received at least one dose of pembrolizumab. The objective response rate among the 25 patients with at least one evaluation during treatment was 56% (95% confidence interval [CI], 35 to 76); 4 patients had a complete response, and 10 had a partial response. With a median follow-up of 33 weeks (range, 7 to 53), relapses occurred in 2 of the 14 patients who had had a response (14%). The response duration ranged from at least 2.2 months to at least 9.7 months. The rate of progression-free survival at 6 months was 67% (95% CI, 49 to 86). A total of 17 of the 26 patients (65%) had virus-positive tumors. The response rate was 62% among patients with MCPyV-positive tumors (10 of 16 patients) and 44% among those with virus-negative tumors (4 of 9 patients). Drug-related grade 3 or 4 adverse events occurred in 15% of the patients. CONCLUSIONS: In this study, first-line therapy with pembrolizumab in patients with advanced Merkel-cell carcinoma was associated with an objective response rate of 56%. Responses were observed in patients with virus-positive tumors and those with virus-negative tumors. (Funded by the National Cancer Institute and Merck; ClinicalTrials.gov number, NCT02267603.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1603702

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Self-citation
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citation
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447

Flagged first, then by citations

Show all 42 references

Research works printed but not linked: 3

10.2307/2281868 · DOI · Paper page
Berger RL, 1996, Am Stat, 50, 314
Behr DS, 2014, Int J Clin Exp Pathol, 7, 7610

Sorted by citations

Items 501–600 of 1,000

The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies
Keung, E. Z.-Y., & Wargo, J. A. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.008 · Cited by 24
Management Recommendations for Merkel Cell Carcinoma—A Danish Perspective
Naseri, S., Steiniche, T., Ladekarl, M. B., Bønnelykke‐Behrndtz, M. L., Hölmich, L. R., Langer, S. W., Venzo, A., Tabaksblat, E. M., Klausen, S., Larsen, M. S., et al. (2020) · Cancers · doi:10.3390/cancers12030554 · Cited by 24
Merkel Cell Carcinoma of the Head and Neck: Epidemiology, Pathogenesis, Current State of Treatment and Future Directions
Yusuf, M. B., McKenzie, G. W., Rattani, A., Tennant, P., Bumpous, J. M., Miller, D. M., & Dunlap, N. (2021) · Cancers · doi:10.3390/cancers13143506 · Cited by 23
The Comprehensive Cancer Center
Aljurf, M., Majhail, N. S., Koh, M., Kharfan-Dabaja, M. A., & Chao, N. J. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-82052-7 · Cited by 24
S2k Guideline – Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – Update 2022
Becker, J. C., Beer, A. J., DeTemple, V. K., Eigentler, T., Flaig, M. J., Gambichler, T., Grabbe, S., Höller, U., Klumpp, B. D., Lang, S., et al. (2023) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14930 · Cited by 23
Proteogenomic identification of an immunogenic antigen derived from human endogenous retrovirus in renal cell carcinoma
Kobayashi, S., Tokita, S., Moniwa, K., Kitahara, K., Iuchi, H., Matsuo, K., Κakizaki, H., Kanaseki, T., & Torigoe, T. (2023) · JCI Insight · doi:10.1172/jci.insight.167712 · Cited by 24
T cell therapies for human polyomavirus diseases
Davies, S. I., & Muranski, P. J. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.08.011 · Cited by 23
Proceedings of the NASHNP Companion Meeting, March 18th, 2018, Vancouver, BC, Canada: Salivary Neuroendocrine Carcinoma—An Overview of a Rare Disease with an Emphasis on Determining Tumor Origin
Chernock, R. D., & Duncavage, E. J. (2018) · Head and Neck Pathology · doi:10.1007/s12105-018-0896-4 · Cited by 23
Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma
Nguyen, A. T., Luu, M., Lu, D. J., Hamid, O., Clair, J. M., Faries, M. B., Gharavi, N. M., Ho, A. S., & Zumsteg, Z. S. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.072 · Cited by 23
p110δ PI3K as a therapeutic target of solid tumours
Xenou, L., & Papakonstanti, E. A. (2020) · Clinical Science · doi:10.1042/cs20190772 · Cited by 23
The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018
Dahl, O., & Brydøy, M. (2019) · Acta Oncologica · doi:10.1080/0284186x.2018.1555375 · Cited by 24
An integrated automated multispectral imaging technique that simultaneously detects and quantitates viral RNA and immune cell protein markers in fixed sections from Epstein-Barr virus-related tumours
Wee, F. Y. T., Alkaff, S. M. F., Lim, J. C. T., Loh, J. J. H., Hilmy, M. H., Ong, C. C. H., Nei, W. L., Jain, A., Lim, A. S.-T., Takano, A. M., et al. (2018) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2018.09.002 · Cited by 22
Effective effectors: How T cells access and infiltrate the central nervous system
Congdon, K. L., Sanchez-Perez, L. A., & Sampson, J. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.007 · Cited by 22
Merkel Cell Carcinoma – Current Controversies and Future Directions
Steven, N. M., Lawton, P. A., & Poulsen, M. G. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.08.012 · Cited by 22
Cancer systems immunology
Reticker-Flynn, N. E., & Engleman, E. G. (2020) · eLife · doi:10.7554/elife.53839 · Cited by 23
Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?
Goff, P. H., Bhakuni, R., Pulliam, T. H., Lee, J. H., Hall, E. T., & Nghiem, P. (2021) · Cancers · doi:10.3390/cancers13143415 · Cited by 23
Self-citation
Neuroendocrine Carcinomas of the Digestive Tract: What Is New?
Pellat, A., Cottereau, A., Terris, B., & Coriat, R. (2021) · Cancers · doi:10.3390/cancers13153766 · Cited by 22
Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management
Plunkett, K. R., Armitage, J. D., Inderjeeth, A., McDonnell, A. M., Waithman, J. C., & Lau, P. K. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1048758 · Cited by 25
A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy
Chen, Z., Yang, X., Chen, Z., Li, M., Wang, W., Yang, R., Wang, Z., Ma, Y., Xu, Y., Ao, S., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03094-0 · Cited by 22
The Second Wave of Immune Checkpoint Inhibitor Tsunami: Advance, Challenges and Perspectives
Kourié, H. R., Awada, G., & Awada, A. H. (2017) · Immunotherapy · doi:10.2217/imt-2017-0029 · Cited by 24
Adjuvant radiation therapy improves patient survival in early‐stage merkel cell carcinoma: A 15‐year single‐institution study
Han, A. Y., Patel, P. B., Anderson, M., Diaz, M. F. P., Chin, R., & John, M. A. S. (2018) · The Laryngoscope · doi:10.1002/lary.27031 · Cited by 22
Trends in the incidence of Merkel cell carcinoma in Victoria, Australia, between 1986 and 2016
Garbutcheon‐Singh, K. B., Curchin, D. J., McCormack, C. J., & Smith, S. D. (2019) · Australasian Journal of Dermatology · doi:10.1111/ajd.13131 · Cited by 22
Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature
Mroue, A., Moujaess, E., Kourié, H. R., Azar, H., Finianos, S., & Chelala, D. N. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103169 · Cited by 22
Neurological complications of immune checkpoint inhibitor cancer immunotherapy
Zivelonghi, C., & Ζεκερίδου, Α. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117424 · Cited by 22
Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions
Pellat, A., Cottereau, A., Palmieri, L., Soyer, P. A., Marchèse, U., Brézault, C., & Coriat, R. (2021) · Cancers · doi:10.3390/cancers13102448 · Cited by 22
CMTM6 as a master regulator of PD-L1
Yaseen, M. M., Abuharfeil, N. M., & Darmani, H. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03171-y · Cited by 25
Comparison Between UMAP and t-SNE for Multiplex-Immunofluorescence Derived Single-Cell Data from Tissue SectionsPreprint
Wu, D., Sheng, J. Y. P., Su-En, G. T., Chevrier, M., Hua, J. L. J., Hon, T. L. K., & Chen, J. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/549659 · Cited by 22
The Problem with Syngeneic Mouse Tumor Models
Lönberg, N. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1046 · Cited by 23
Biomarkers for predicting the outcome of various cancer immunotherapies
Jafarzadeh, L., Khakpoor-Koosheh, M., Mirzaei, H., & Mirzaei, H. R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103161 · Cited by 21
Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications
Wong, C., Lam, T.-H., Liao, S.-Y., Lau, Y., Tse, H., & So, B. Y. F. (2023) · Biomedicines · doi:10.3390/biomedicines11010107 · Cited by 21
FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription
Li, X., Gao, L., Wang, B., Hu, J., Yu, Y., Gu, B., Xiang, L., Li, X., Li, H., Zhang, T., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009565 · Cited by 21
Factors associated with advanced-stage Merkel cell carcinoma at initial diagnosis and the use of radiation therapy: Results from the National Cancer Database
Trofymenko, O., Zeitouni, N. C., & Kurtzman, D. J. B. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.03.019 · Cited by 21
Treatment and survival of Merkel cell carcinoma since 1993: A population-based cohort study in The Netherlands
Uitentuis, S. E., Louwman, M. W. J., van Akkooi, A. C. J., & Bekkenk, M. W. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.01.042 · Cited by 21
Predictive Biomarkers for PD-1 and PD-L1 Immune Checkpoint Blockade Therapy
Song, Y., Li, Z., Xue, W., & Zhang, M. (2019) · Immunotherapy · doi:10.2217/imt-2018-0173 · Cited by 21
T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma
Farah, M., Reuben, A., Spassova, I., Yang, R. K., Kubat, L., Nagarajan, P., Ning, J., Li, W., Aung, P. P., Curry, J. L., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.02.031 · Cited by 21
Glucose-6-phosphate dehydrogenase correlates with tumor immune activity and programmed death ligand-1 expression in Merkel cell carcinoma
Nakamura, M., Nagase, K., Yoshimitsu, M., Magara, T., Nojiri, Y., Kato, H., Kobayashi, T., Teramoto, Y., Yasuda, M., Wada, H., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001679 · Cited by 21
Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review
Ouyang, T., Cao, Y., Kan, X., Chen, L., Ren, Y., Sun, T., Yan, L., Xiong, B., Liang, B., & Zheng, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.621639 · Cited by 21
Does Neutron Radiation Therapy Potentiate an Immune Response to Merkel Cell Carcinoma?
Schaub, S. K., Stewart, R. D., Sandison, G. A., Arbuckle, T., Liao, J. J., Laramore, G. E., Zeng, J., Rengan, R., Tseng, Y. D., Mayr, N. A., et al. (2018) · International Journal of Particle Therapy · doi:10.14338/ijpt-18-00012.1 · Cited by 21
Self-citation
Advances in Merkel cell carcinoma from a pathologist's perspective
Barksdale, S. K. (2017) · Pathology · doi:10.1016/j.pathol.2017.07.003 · Cited by 20
PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma
Barkdull, S., & Brownell, I. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1394552 · Cited by 20
Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis
Torralba, E. G., Spada, F., Lim, K. H. J., Jacobs, T., Barriuso, J., Mansoor, W., McNamara, M. G., Hubner, R. A., Manoharan, P., Fazio, N., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102168 · Cited by 20
Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates
Seyhan, A. A., & Carini, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010041 · Cited by 22
Risk of Multiple Primary Cancers in Patients With Merkel Cell Carcinoma
Eid, E. S., Maloney, N. J., Cai, Z. R., Zaba, L. C., Kibbi, N., John, E. M., & Linos, E. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2023.2849 · Cited by 20
DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates antitumor immunity
Kureshi, R., Bello, E., Kureshi, C. T. S., Walsh, M. J., Lippert, V., Hoffman, M. T., Dougan, M. L., Longmire, T. A., Wichroski, M. J., & Dougan, S. K. (2023) · Science Advances · doi:10.1126/sciadv.adk1853 · Cited by 20
Merkel cell polyomavirus-specific and CD39+CLA+ CD8 T cells as blood-based predictive biomarkers for PD-1 blockade in Merkel cell carcinoma
Ryu, H., Bi, T., Pulliam, T. H., Sarkar, K., Church, C. D., Kumar, N., Mayer-Blackwell, K., Jani, S., Ramchurren, N., Hansen, U. K., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101390 · Cited by 20
Self-citation
Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences
Davar, D., & Bahary, N. (2018) · Targeted Oncology · doi:10.1007/s11523-017-0547-9 · Cited by 20
Liquid Biopsies and Cancer Immunotherapy
Thompson, J. R., & Menon, S. P. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000307 · Cited by 20
Self-citation
Programmed death receptor Ligand 1 expression in eyelid sebaceous carcinoma: a consecutive case series of 41 patients
Xu, S., Yu, H., Fu, G., Fan, X., & Jia, R. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13833 · Cited by 20
Merkel Cell Carcinoma in the HIV-1/AIDS Patient
Goldstein, R. H., & DeCaprio, J. A. (2018) · Cancer treatment and research · doi:10.1007/978-3-030-03502-0_8 · Cited by 20
Personalisierte Medizin in der Behandlung von periokulären Tumoren
Rokohl, A. C., Koch, K. R., Mor, J. M., Loreck, N., Schlaak, M. S., Mauch, C., Bechrakis, N. E., Mohi, A., Kakkassery, V., & Heindl, L. M. (2020) · Der Ophthalmologe · doi:10.1007/s00347-019-01034-z · Cited by 20
Immunobiology of Merkel cell carcinoma
Samimi, M., Kervarrec, T., & Touzé, A. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000608 · Cited by 20
CAR-T Cells for the Treatment of Lung Cancer
Chocarro, L., Arasanz, H., Fernández, L., Blanco, E., Echaide, M., Bocanegra, A., Teijeira, L., Garnica, M., Morilla, I., Martínez-Aguillo, M., et al. (2022) · Life · doi:10.3390/life12040561 · Cited by 21
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma
Church, C. D., Pulliam, T., Longino, N. V., Park, S. Y., Smythe, K. S., Makarov, V., Riaz, N., Jing, L., Amezquita, R. A., Campbell, J. S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005328 · Cited by 20
Self-citation
Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta‐analysis
Malaty, M. M., Amarasekera, A. T., Li, C., Scherrer‐Crosbie, M., & Tan, T. C. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13831 · Cited by 20
Targeting collagen in tumor extracellular matrix as a novel targeted strategy in cancer immunotherapy
Liu, J., Pan, D., Huang, X., Wang, S., Chen, H., Zhu, Y. Z., & Ye, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1225483 · Cited by 19
Research progress and challenges of the PD-1/PD-L1 axis in gliomas
Jiacheng, D., Cui, J., Ying, G., Shaohua, W., Wenhui, L., & Hong, X. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01305-6 · Cited by 19
Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician
Hansen, E., Wang, X., Case, A. A., Puzanov, I. J., & Smith, T. (2018) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2018.05.015 · Cited by 19
Immunotherapy for Merkel Cell Carcinoma
Nagase, K., & NARISAWA, Y. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0574-5 · Cited by 19
Nanotechnology-Based Platforms to Improve Immune Checkpoint Blockade Efficacy in Cancer Therapy
Lahori, D., & Varamini, P. (2020) · Future Oncology · doi:10.2217/fon-2020-0720 · Cited by 19
Scientific and clinical developments in Merkel cell carcinoma: A polyomavirus-driven, often-lethal skin cancer
Akaike, T., & Nghiem, P. (2021) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2021.10.004 · Cited by 19
Self-citation
Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective
Allegra, A., Gioacchino, M. D., Tonacci, A., Petrarca, C., & Gangemi, S. (2021) · Nanomaterials · doi:10.3390/nano11112792 · Cited by 19
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab
Brüggemann, C., Kirchberger, M. C., Goldinger, S. M., Weide, B., Konrad, A., Erdmann, M., Schadendorf, D., Croner, R. S., Krähenbühl, L., Kähler, K. C., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2450-2 · Cited by 19
Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patients
Lodde, G. C., Leiter, U., Gesierich, A., Eigentler, T., Hauschild, A., Pföhler, C., Gambichler, T., Herbst, R. A., Meier, F. E., Hassel, J. C., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115406 · Cited by 18
Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)
Grignani, G., Rutkowski, P., Lebbé, C., Guida, M., Gaudy‐Marqueste, C., Spagnolo, F., Burgess, M. A., Morano, F., Montaudié, H., Depenni, R., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012478 · Cited by 18
Self-citation
WOMEN IN CANCER THEMATIC REVIEW: Systemic therapies in neuroendocrine tumors and novel approaches toward personalized medicine
Pavel, M. E., & Sers, C. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0370 · Cited by 19
Efficacy and safety of PD-1/PD-L1 inhibitors in patients with Merkel Cell Carcinoma: a systematic review and Meta-analysis
de Moraes, F. C. A., Kreuz, M., de Lara, I. C. A., Lôbo, A. D. O. M., & Burbano, R. M. R. (2024) · BMC Cancer · doi:10.1186/s12885-024-13129-1 · Cited by 18
An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma
Pham, J. P., Staeger, R., Joshua, A. M., Liu, J., da Silva, I. P., Dummer, R., & Goldinger, S. M. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115121 · Cited by 18
Avelumab: A Review of Its Application in Metastatic Merkel Cell Carcinoma
Joseph, J., Zobniw, C. M., Davis, J. E., Anderson, J. E., & Trinh, V. A. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018768809 · Cited by 18
The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach
Tan, A. S., Yeong, J. P.-S., Lai, C. P. T., Ong, C. H. C., Lee, B. T. K., Lim, J. C. T., Thike, A. A., Iqbal, J., Dent, R. A., Lim, E. H., et al. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02635-4 · Cited by 18
Tumor Ulceration, Reduced Infiltration of CD8-Lymphocytes, High Neutrophil-to-CD8-Lymphocyte Ratio and Absence of MC Virus are Negative Prognostic Markers for Patients with Merkel Cell Carcinoma
Naseri, S., Steiniche, T., Georgsen, J. B., Thomsen, R., Ladekarl, M. B., Heje, M., Damsgaard, T. E., & Bønnelykke‐Behrndtz, M. L. (2020) · Cancers · doi:10.3390/cancers12040888 · Cited by 18
Positron Emission Tomography in Merkel Cell Carcinoma
Sachpekidis, C., Sidiropoulou, P., Hassel, J. C., Drakoulis, N., & Dimitrakopoulou‐Strauss, A. (2020) · Cancers · doi:10.3390/cancers12102897 · Cited by 18
Clinical impact of immunotherapy in Merkel cell carcinoma patients: A systematic review and meta-analysis
Garza‐Dávila, V. F., Valdespino‐Valdes, J., Barrera, F. J., Ocampo‐Candiani, J., & Garza‐Rodríguez, V. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.04.024 · Cited by 18
Genomic, Microbial and Immunological Microenvironment of Colorectal Polyps
Tse, B. C. Y., Welham, Z., Engel, A. F., & Molloy, M. P. (2021) · Cancers · doi:10.3390/cancers13143382 · Cited by 20
Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma
In, G. K., Nallagangula, A., Choi, J. S., Tachiki, L. M. L., Blackburn, M. J., Capone, S., Bollin, K. B., Reuben, D. Y., Shirai, K., Zhang-Nunes, S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004839 · Cited by 18
Self-citation
Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors
Blanco, E., Chocarro, L., Fernández, L., Bocanegra, A., Arasanz, H., Echaide, M., Garnica, M., Piñeiro‐Hermida, S., Kochan, G. T., & Escors, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032676 · Cited by 18
The Evolving Treatment Landscape of Merkel Cell Carcinoma
Singh, N., McClure, E., Akaike, T., Park, S. Y., Huynh, E. T., Goff, P. H., & Nghiem, P. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01118-8 · Cited by 18
Self-citation
Stability and Hopf bifurcation of a tumor–immune system interaction model with an immune checkpoint inhibitor
Shi, S., Huang, J., Kuang, Y., & Ruan, S. (2022) · Communications in Nonlinear Science and Numerical Simulation · doi:10.1016/j.cnsns.2022.106996 · Cited by 17
N7-methylguanosine regulatory genes well represented by METTL1 define vastly different prognostic, immune and therapy landscapes in adrenocortical carcinoma.
Xu, F., Cai, D., Liu, S., He, K., Chen, J., Li, Q., Chong, T., Li, X., & Ren, B. (2023) · PubMed Central · Cited by 17
Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma
Tachiki, L. M. L., Hippe, D. S., Silva, K. W., Hall, E. T., McCamy, W., Fritzsche, D., Perdue, A. M., Majovski, J., Pulliam, T. H., Goldstein, D. A., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03539-8 · Cited by 17
Self-citation
Merkel Cell Carcinoma
Strong, J., Hallaert, P., & Brownell, I. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.05.013 · Cited by 18
The prognostic and therapeutic value of the tumor microenvironment and immune checkpoints in pancreatic neuroendocrine neoplasms
Chen, Z., Lin, S., Liang, F., Hou, Z., Yang, Y., Huang, H., & Pan, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-75882-4 · Cited by 17
Harnessing the Immune System as a Therapeutic Tool in Virus-Associated Cancers
Santana-Dávila, R., Bhatia, S., & Chow, L. Q. M. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4574 · Cited by 17
Self-citation
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Granier, C., Vinatier, E., Colin, E., Mandavit, M., Dariane, C., Verkarre, V., Biard, L., Zein, R. M. E., Lesaffre, C., Galy–Fauroux, I., et al. (2018) · Journal of Visualized Experiments · doi:10.3791/56606 · Cited by 17
Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma
Lara, K., In, G. K., Matcuk, G. R., Mehta, A., & Hu, J. S. (2018) · JAAD Case Reports · doi:10.1016/j.jdcr.2018.10.003 · Cited by 17
The Landmark Series: Non-melanoma Skin Cancers
Lee, A. Y., & Berman, R. S. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07831-9 · Cited by 17
Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies
Yang, R. K., Qing, Y., Jelloul, F. Z., Routbort, M. J., Wang, P., Shaw, K. R. M., Zhang, J., Lee, J., Medeiros, L. J., Kopetz, S., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27466 · Cited by 17
High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors
Wolkow, N., Jakobiec, F. A., Afrogheh, A., Pai, S. I., & Faquin, W. C. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.07.031 · Cited by 17
Pancreatic Diseases and Microbiota: A Literature Review and Future Perspectives
Gesualdo, M., Rizzi, F., Bonetto, S., Rizza, S., Cravero, F., Saracco, G. M., & Angelis, C. G. D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113535 · Cited by 17
Characterization of clinical outcomes after shorter course hypofractionated and standard-course radiotherapy for stage I-III curatively-treated Merkel cell carcinoma
Liu, K. X., Milligan, M., Schoenfeld, J. D., Tishler, R. B., Ng, A. K., Devlin, P. M., Fite, E., Rabinowits, G., Hanna, G. J., Silk, A. W., et al. (2022) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2022.05.012 · Cited by 17
Current In Vitro and In Vivo Models to Study MCPyV-Associated MCC
Loke, A. S. W., Lambert, P. F., & Spurgeon, M. E. (2022) · Viruses · doi:10.3390/v14102204 · Cited by 17
Merkel cell carcinoma: an update
DeCoste, R. C., Carter, M. D., Ly, T. Y., Gruchy, J. R., Nicolela, A. P., & Pasternak, S. (2023) · Human Pathology · doi:10.1016/j.humpath.2023.03.004 · Cited by 17
Efficacy of isolated limb perfusion (ILP) in patients with Merkel cell carcinoma (MCC): A multicenter experience
van Veenendaal, L. M., Madu, M. F., Tesselaar, M. E. T., Verhoef, C. K., Grünhagen, D. J., & van Akkooi, A. C. J. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.07.015 · Cited by 17
Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
Bobrowicz, M., Zagożdżon, R., Domagała, J., Vasconcelos‐Berg, R., Guenova, E., & Winiarska, M. (2019) · Cancers · doi:10.3390/cancers11101420 · Cited by 17
Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial
Lambert, J., Marrel, A., D’Angelo, S. P., Burgess, M. A., Chmielowski, B., Fazio, N., Gambichler, T., Grob, J., Lebbé, C., Robert, C., et al. (2020) · Patient · doi:10.1007/s40271-020-00428-5 · Cited by 17
Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies
Gao, P., Li, X., Duan, Z., Wang, Y., Li, Y., Wang, J., Luo, K., & Chen, J. (2025) · MedComm · doi:10.1002/mco2.70274 · Cited by 16
Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors
Milhem, M. M., Wise-Draper, T. M., Chandra, S., Hanna, G. J., Laux, D. E., Medina, T. M., Ansstas, G., DAUD, A. I., Kelly, C. M., O'Day, S. J., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011651 · Cited by 16
Self-citation
CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer
Huang, H., Yao, Y., Shen, L., Jiang, J., Zhang, T., Xiong, J., Li, J., Sun, S., Zheng, S., Jia, F., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1759 · Cited by 16
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
Patel, S. P., Othus, M. K. D., Chae, Y. K., Huynh, T. R., Tan, B. R., Kuzel, T. M., McLeod, C. M., Lopez, G., Chen, H. X., Sharon, E., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009074 · Cited by 16
Self-citation
Setting “cold” tumors on fire: Cancer therapy with live tumor-targeting bacteria
Manole, S., Nguyen, D.-H., Min, J.-J., Zhou, S., & Forbes, N. (2024) · Med · doi:10.1016/j.medj.2024.11.002 · Cited by 17
Is this the end of cytotoxic chemotherapy in Merkel cell carcinoma?
Rabinowits, G. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s126640 · Cited by 16

Authors: Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., Friedlander, P. A., Kluger, H. M., Kohrt, H. E., Lundgren, L., Margolin, K., Mitchell, A., Olencki, T., Pardoll, D. M., Reddy, S. A., Shantha, E. M., Sharfman, W. H., Sharon, E., Shemanski, L. R., Shinohara, M. M., Sunshine, J. C., Taube, J. M., Thompson, J. A., Townson, S. M., Yearley, J. H., Topalian, S. L., & Cheever, M. A.
Affiliations: Johns Hopkins University (US)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Mount Sinai Hospital (US)
ORCID: Nghiem, Paul T.
Bhatia, Shailender
Lipson, Evan J.
Kudchadkar, Ragini R.
Miller, Natalie J.
Berry, Sneha
Chartash, Elliot K.
Daud, Adil
Fling, Steven P.
Friedlander, Philip A.
Kluger, Harriet M.
Lundgren, Lisa
Margolin, Kim
Pardoll, Drew M.
Reddy, Sunil A.
Sharfman, William H.
Sharon, Elad
Shinohara, Michi M.
Sunshine, Joel C.
Taube, Janis M.
Thompson, John A.
Topalian, Suzanne L.
Cheever, Martin A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2016-06-30
Volume: 374
Issue: 26
Pages: 2542-2552
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1603702
PMC: PMC4927341
OpenAlex: W2339890238
Cited by: 1,258
References: 42
Citations by year: 2026: 40 · 2025: 68 · 2024: 76 · 2023: 86 · 2022: 104 · 2021: 141 · 2020: 166 · 2019: 172 · 2018: 187 · 2017: 174 · 2016: 40
FWCI: 103.02
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Institutes of Health (5u01ca154967-06)
National Cancer Institute (U01-CA-154967, R01CA162522, 1U01CA154967, K24CA139052, UM1CA154967, R01CA142779, P30CA006973)
National Institute of General Medical Sciences (T32GM007266)
Topics: Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
Keywords: Merkel cell carcinoma, pembrolizumab, anti-PD-1 therapy, immune checkpoint inhibitors, Merkel cell polyomavirus, PD-L1 expression, first-line therapy, objective response rate, progression-free survival, cutaneous squamous cell carcinoma, immune-related adverse events, treatment-related adverse events, treatment duration, drug safety and efficacy
MeSH terms: Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasm Staging, Recurrence, Skin Neoplasms, Carcinoma, Merkel Cell, Disease-Free Survival, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks